Business
Kura Oncology Reports First Quarter 2023 Financial Results
– Evolving data from Phase 1 trial of ziftomenib in NPM1-mutant AML to be presented at EHA – – Site activation and enrollment in Phase 2 registration-directed
About this update from Kura Oncology, Inc.
[{"type":"text","content":"– Evolving data from Phase 1 trial of ziftomenib in NPM1-mutant AML to be presented at EHA – – Site activation and enrollment in Phase 2 registration-directed trial of ziftomenib in NPM1-mutant AML outperforming projections – – First combination study of ziftomenib in NPM1-mutant and KMT2A-rearranged AML to dose first patients in the second quarter of 2023 – – Preclinical data highlighting potential use of FTIs in combination with multiple targeted therapies presented at AACR – – IND for KO-2806, a next-generation FTI, cleared by FDA – – $406 million in cash, equivalents and investments provide runway into fourth quarter of 2025 – – Management to host webcast and conference call today at 4:30 p.m. ET – SAN DIEGO, May 10, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported first quarter 2023 financial results and provided a corporate update. “Our conviction in ziftomenib and its potential to be the best-in-class menin inhibitor continues to increase,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology. “This confidence is supported by one of the highest complete response rates reported for a targeted therapy in the setting of relapsed/refractory leukemia and is reinforced by the rapid pace of enrollment in our ongoing registration-directed trial in NPM1-mutant acute myeloid leukemia (AML). We are also encouraged by the durable remissions in our Phase 1 trial, driven primarily by the single-agent activity of ziftomenib, and we look forward to presenting an update at the European Hematology Association (EHA) Congress next month. In parallel, we aim to broaden the opportunity for ziftomenib through a series of combination studies and remain on track to initiate the first of these studies, KOMET-007, later this quarter.” Recent Highlights Evolving data from Phase 1 trial of ziftomenib in NPM1-mutant AML to be presented at EHA – Kura expects to present updated data as of an early April data cutoff at EHA in June. Ziftomenib continues to demonstrate significant clinical activity in patients with heavily pretreated and co-mutated relapsed or refractory NPM1-mutant AML. As of a January 31st data cutoff, six of the 20 NPM1-mutant patients treated at the...